(1 - 20 von 25
)
Genomic Health : Oncotype DX® Predicts 10-year Risk of Developing...
www.marketscreener.com
March 29, Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients...
Home Page - Cypriot Biotech Database
www.cypriotbiotech.com
Twitter LinkedIn Google+ ... Phil Febbo, M.D., chief medical officer, Genomic Health and former professor of medicine and urology at the University of California, ...
Genomic Health announces Medicare coverage for Oncotype DX prostate...
www.news-medical.net
... immediate aggressive treatment resulting in unnecessary surgery and radiation," said Phil Febbo, M.D., chief medical officer, Genomic Health ...
Home Page - Maltese Biotech Database
www.maltesebiotech.com
Twitter LinkedIn Google+ ... validation of genomic information can transform cancer treatment," said Phil Febbo, M.D., chief medical officer, Genomic Health.
sortiert nach Relevanz / Datum